NEW YORK–(BUSINESS WIRE)–TriGemX Bio (formerly known as Kallyope), a biotechnology company focused on developing a first-in-class medicine for the treatment of migraine, today announced the closing of a $94 million financing co-led by The Column Group, TCGX, and Viking Global Investors, with participation from additional investors. The funds will be used to advance the clinical development of the company’s lead program, elismetrep, a novel, oral TRPM8 channel blocker, which is currently in Pha